CGP 3466B has no effect on disease course of (G93A) mSOD1 transgenic mice

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 5, Issue 4, 2004, Pages 220-225

  Groeneveld, Geert J ^a   van Muiswinkel, Freek L ^a   de Leeuw van Weenen, Judith ^a   Blauw, Hylke ^a   Veldink, Jan H ^a   Wokke, John H J ^a   van den Berg, Leonard H ^a   Bär, Peter R ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

( ) deprenyl; Amyotrophic lateral sclerosis; Apoptosis; TCH 346

Indexed keywords

AMINE; CGP 3466B; DIBENZO[B,F]OXEPIN 10 YLMETHYLMETHYLPROP 2 YNYLAMINE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEATH; DISEASE COURSE; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; MALE; MOTONEURON; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SPINAL CORD VENTRAL HORN; SURVIVAL; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MOTOR NEURONS; OXEPINS; SUPEROXIDE DISMUTASE;

EID: 12344314101     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/14660820410019530     Document Type: Article

References (37)

1. Yoshiyama Y, Yamada T, Asanuma K, Asahi T. Apoptosis related antigen, Le(Y) and nick-end labelling are positive in spinal motor neurons in amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 1994; 88(3): 207-211.
2. Mu X, He J, Anderson DW, Trojanowski JQ, Springer JE. Altered expression of bcl-2 and bax mRNA in amyotrophic lateral sclerosis spinal cord motor neurons. Ann Neurol 1996; 40(3): 379-386.
3. Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999; 58(5): 459-471.
4. Kostic V, Jackson Lewis V, de Bilbao F, Dubois Dauphin M, Przedborski S. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997; 277(5325): 559-562.
5. Friedlander RM, Brown RH, Gagliardini V, Wang J, Yuan J. Inhibition of ICE slows ALS in mice. Nature 1997; 388(6637): 31-31.
6. Vukosavic S, Stefanis L, Jackson-Lewis V et al. Delaying caspase activation by Bcl-2: a clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2000; 20(24): 9119-9125.
7. Li M, Ona VO, Guegan C et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000; 288(5464): 335-339.
8. Yamashita S, Mita S, Arima T et al. Bcl-2 expression by retrograde transport of adenoviral vectors with Cre- loxP recombination system in motor neurons of mutant SOD1 transgenic mice. Gene Ther 2001; 8(13): 977-986.
9. Kragten E, Lalande I, Zimmermann K et al. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem 1998; 273(10): 5821-5828.
10. Paterson IA, Waldmeier P, Boulton AA. CGP3466 and CGP3466B prevent cytosine arabinoside-induced apoptosis in cultures of cerebellar neurons. J Neurochem 1998; 70(suppl1): S11B.
11. Andringa G, van Oosten RV, Stoof JC, Cools AR. Systemic administration of CGP3466B prevents enzymatic and behavioural deficits in 6-OHDA treated rats. Soc Neurosci Abstr 1999; 25: 133.20.
12. Waldmeier PC, Boulton AA, Cools AR, Kato AC, Tatton WG. Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Transm (Suppl) 2000; (60): 197-214.
13. Sirover MA. New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta 1999; 1432(2): 159-184.
14. Sawa A, Khan AA, Hester LD, Snyder SH. Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and non-neuronal cell death. Proc Natl Acad Sci USA 1997; 94(21): 11669-11674.
15. Ishitani R, Tanaka M, Sunaga K, Katsube N, Chuang DM. Nuclear localisation of overexpressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons undergoing apoptosis. Mol Pharmacol 1998; 53(4): 701-707.
16. Saunders PA, Chen RW, Chuang DM. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase isoforms during neuronal apoptosis. J Neurochem 1999; 72(3): 925-932.
17. Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, Tatton WG. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 2000; 57(1): 2-12.
18. Tatton WG, Chalmers-Redman RM, Ju WJ et al. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 2002; 301(2): 753-764.
19. Huebscher KJ, Lee J, Rovelli G et al. Protein isoaspartyl methyltransferase protects from Bax-induced apoptosis. Gene 1999; 240(2): 333-341.
20. Sagot Y, Toni N, Perrelet D et al. An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motor neuron disease. Br J Pharmacol 2000; 131(4): 721-728.
21. Andreassen OA, Dedeoglu A, Friedlich A et al. Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Exp Neurol 2001; 168(2): 419-424.
22. Gurney ME, Pu H, Chiu AY et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 1994; 264(5166): 1772-1775.
23. Gurney ME, Cutting FB, Zhai P, Andrus PK, Hall ED. Pathogenic mechanisms in familial amyotrophic lateral sclerosis due to mutation of Cu/Zn superoxide dismutase. Pathol Biol Paris 1996; 44(1): 51-56.
24. Barneoud P, Lolivier J, Sanger DJ, Scatton B, Moser P. Quantitative motor assessment in FALS mice: a longitudinal study. Neuroreport 1997; 8(13): 2861-2865.
25. Adams JC. Heavy metal intensification of DAB-based HRP reaction product. J Histochem Cytochem 1981; 29(6): 775.
26. Andringa G, Cools AR. The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey. J Neural Transm (Suppl) 2000; (60): 215-225.
27. Park DS, Morris EJ, Stefanis L et al. Multiple pathways of neuronal death induced by DNA-damaging agents, NGF deprivation, and oxidative stress. J Neurosci 1998; 18(3): 830-840.
28. Berry MD, Boulton AA. Glyceraldehyde-3-phosphate dehydrogenase and apoptosis. J Neurosci Res 2000; 60(2): 150-154.
29. Dastoor Z, Dreyer JL. Potential role of nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase in apoptosis and oxidative stress. J Cell Sci 2001; 114(Pt 9): 1643-1653.
30. Raoul C, Estevez AG, Nishimune H et al. Motor neuron death triggered by a specific pathway downstream of Fas potentiation by ALS-linked SOD1 mutations. Neuron 2002; 35(6): 1067-1083.
31. Dal Canto MC, Gurney ME. A low expressor line of transgenic mice carrying a mutant human Cu/Zn superoxide dismutase (SOD1) gene develops pathological changes that most closely resemble those in human amyotrophic lateral sclerosis. Acta Neuropathol Berl 1997; 93(6): 537-550.
32. Waibel S, Malessa R, Reuter A, Blaugrund E, Ludolph AC. The MAO-inhibitor rasagiline is neuroprotective in ALS. Amyotroph.Lateral.Scler Other Motor Neuron Disord 2002; 3(Suppl 2): 71, p.38.
33. Kunikowska G, Gallagher I, Glover V, Clow A, Jenner P. Effects of short- and long-term (-)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brain. Brain Res 2002; 953(1-2): 1-11.
34. Kuntz C, Kinoshita Y, Beal MF, Donehower LA, Morrison RS. Absence of p53: no effect in a transgenic mouse model of familial amyotrophic lateral sclerosis. Exp Neurol 2000; 165(1): 184-190.
35. Prudlo J, Koenig J, Graser J et al. Motor neuron cell death in a mouse model of FALS is not mediated by the p53 cell survival regulator. Brain Res 2000; 879(1-2): 183-187.
36. de la Monte SM, Sohn YK, Ganju N, Wands JR. P53- and CD95-associated apoptosis in neurodegenerative diseases. Lab Invest 1998; 78(4): 401-411.
37. Waldmeier PC. Prospects for antiapoptotic drug therapy of neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27(2): 303-321.